BCL-XL targeting has additionally been demonstrated to sensitise medulloblastoma cells to MLN8237 treatment [96] as well as to ionising radiation [97], while synergy between ABT-263 and vincristine has also been attributed to its BCL-XL-targeting ability [98]. The gene discussed is BCL2L1; the disease is medulloblastoma.